NOOTROPICS
PT-141 — Bremelanotide libido peptide
Also known as: Bremelanotide, Vyleesi
PT-141 (bremelanotide, Vyleesi) is a synthetic melanocortin receptor agonist derived from Melanotan-II. FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) — the only peptide acting on CNS rather than vascular pathways.
Prices
Mechanism
Acts on hypothalamic melanocortin pathways to raise libido centrally — distinct from PDE-5 inhibitor vascular action.
Clinical data
RECONNECT trials (Kingsberg 2019): significant improvement in desire and satisfaction vs placebo in premenopausal women with HSDD.
Protocol
0.5–2 mg SC, 30–60 min before activity. Titrate from low dose; max 1 dose per 24h.
Frequently asked questions
Buy in EU?
Yes — research-grade only, EU shipping.
Men or women?
Both — FDA-approved in women but trials show efficacy in both sexes.
Research use only. Not for human consumption.